ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pemigatinib

Also written as “Pemigatinib”.

Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.

Drug pagePemigatinib: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 29, 201816 company-led studies, 1 open or runningNext primary completion: Feb 25, 2031 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyteits history only131 open or runningphase 3since Aug 29, 2018Jan 30, 2015Feb 25, 2031phase 2 · NCT07862998
Innovent Biologicsits history only20 open or runningphase 2since Jan 20, 2020Jan 20, 2020none ahead
Hoffmann-La Roche10 open or runningphase 2since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named pemigatinibINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Apr 5, 2018First study: phase 2 study in Neoplasms, Unknown PrimaryFirst studyNCT03498521 · 529 enrolled · Australia, Austria, Brazil and more

TargetBeta

“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
infigratinibruleBridgeBiophase 317
futibatinibruleOtsukaphase 310

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more2CompletedFeb 14, 2023529

How it is read

Names in the registry

  • “Pemigatinib”, 15 entries
  • “pemigatinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.